EPO published patent application EP4048702A1 for Merus B.V., covering bispecific antibody compositions and methods for treating HER2 and HER3 positive cancers. The A1 publication includes the international search report and designates 32 European contracting states. IPC classifications indicate therapeutic applications (A61P 35/00) and protein compositions (C07K 16/32).

Pharmaceutical and biotechnology companies developing HER2/HER3 targeted therapies should review the patent claims for potential licensing requirements or freedom-to-operate concerns. The patent grants exclusivity in designated states upon grant. No immediate compliance actions are required as patent publications are informational; actual enforcement occurs through national courts upon patent grant.